End-of-day quote
Shenzhen S.E.
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
12.64
CNY
|
-6.16%
|
|
+10.78%
|
+7.03%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,809
|
5,872
|
8,639
|
7,813
|
7,929
|
6,486
|
Enterprise Value (EV)
1 |
5,226
|
5,521
|
7,481
|
7,725
|
7,906
|
6,569
|
P/E ratio
|
18.9
x
|
17.3
x
|
29.4
x
|
16.3
x
|
20.6
x
|
36.9
x
|
Yield
|
1.07%
|
-
|
0.65%
|
1.31%
|
0.97%
|
0.6%
|
Capitalization / Revenue
|
8.8
x
|
8.17
x
|
14
x
|
6.99
x
|
5.59
x
|
5.92
x
|
EV / Revenue
|
7.92
x
|
7.69
x
|
12.2
x
|
6.92
x
|
5.58
x
|
6
x
|
EV / EBITDA
|
14.3
x
|
13.3
x
|
25.6
x
|
15.9
x
|
17.3
x
|
21.7
x
|
EV / FCF
|
-96.1
x
|
-27.2
x
|
-28.1
x
|
-18.3
x
|
-1,204
x
|
-21.6
x
|
FCF Yield
|
-1.04%
|
-3.67%
|
-3.56%
|
-5.45%
|
-0.08%
|
-4.62%
|
Price to Book
|
3.72
x
|
3.37
x
|
2.97
x
|
3.43
x
|
3.13
x
|
2.21
x
|
Nbr of stocks (in thousands)
|
4,79,288
|
4,71,614
|
5,43,333
|
5,43,333
|
5,51,008
|
5,49,178
|
Reference price
2 |
12.12
|
12.45
|
15.90
|
14.38
|
14.39
|
11.81
|
Announcement Date
|
25/03/19
|
27/02/20
|
16/04/21
|
29/03/22
|
27/03/23
|
15/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
660.2
|
718.4
|
614.9
|
1,117
|
1,418
|
1,095
|
EBITDA
1 |
365.9
|
414.3
|
292
|
485.5
|
458.2
|
302.7
|
EBIT
1 |
329.2
|
375.4
|
252.9
|
441.1
|
397.5
|
169.5
|
Operating Margin
|
49.87%
|
52.26%
|
41.13%
|
39.49%
|
28.04%
|
15.49%
|
Earnings before Tax (EBT)
1 |
356.5
|
398.7
|
315
|
584.7
|
442.5
|
211
|
Net income
1 |
307.4
|
343.7
|
272.3
|
479.8
|
383.7
|
192.3
|
Net margin
|
46.56%
|
47.84%
|
44.28%
|
42.95%
|
27.07%
|
17.57%
|
EPS
2 |
0.6400
|
0.7200
|
0.5400
|
0.8800
|
0.7000
|
0.3200
|
Free Cash Flow
1 |
-54.36
|
-202.6
|
-266.1
|
-421.1
|
-6.568
|
-303.7
|
FCF margin
|
-8.23%
|
-28.2%
|
-43.28%
|
-37.69%
|
-0.46%
|
-27.75%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.1300
|
-
|
0.1030
|
0.1880
|
0.1400
|
0.0710
|
Announcement Date
|
25/03/19
|
27/02/20
|
16/04/21
|
29/03/22
|
27/03/23
|
15/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
83.6
|
Net Cash position
1 |
583
|
351
|
1,158
|
87.9
|
22.5
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
0.2762
x
|
Free Cash Flow
1 |
-54.4
|
-203
|
-266
|
-421
|
-6.57
|
-304
|
ROE (net income / shareholders' equity)
|
21.6%
|
20.8%
|
11.7%
|
19.8%
|
15.8%
|
7.04%
|
ROA (Net income/ Total Assets)
|
13.5%
|
12.6%
|
5.74%
|
7.77%
|
6.49%
|
2.26%
|
Assets
1 |
2,272
|
2,729
|
4,741
|
6,174
|
5,917
|
8,526
|
Book Value Per Share
2 |
3.260
|
3.700
|
5.360
|
4.190
|
4.590
|
5.340
|
Cash Flow per Share
2 |
0.3900
|
1.070
|
2.130
|
0.9200
|
0.9900
|
2.770
|
Capex
1 |
218
|
446
|
579
|
707
|
380
|
245
|
Capex / Sales
|
32.97%
|
62.1%
|
94.08%
|
63.32%
|
26.8%
|
22.34%
|
Announcement Date
|
25/03/19
|
27/02/20
|
16/04/21
|
29/03/22
|
27/03/23
|
15/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +7.03% | 932M | | +19.62% | 43.27B | | +24.52% | 22.92B | | +20.29% | 15.43B | | +7.48% | 12.95B | | +42.51% | 11.83B | | -8.84% | 6.91B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.13% | 5.55B |
Generic Pharmaceuticals
|